AbbVie and Anima collaborate for mRNA biology modulators

pharmafile | January 11, 2023 | News story | Research and Development  

AbbVie and Amina Biotech have announced their collaboration for the discovery and development of mRNA biology modulators focusing on three oncology and immunology targets.

Throughout their collaboration, the companies will utilise Anima’s mRNA Lightning platform as well as AbbVie’s oncology and immunology expertise. AbbVie will also gain exclusive licensing rights as well as developing and marketing the programmes. Anima is set to receive $42m in an upfront payment, alongside option fees and R&D milestone payments up to the value of $540m.

As well as having the opportunity to receive further royalties and milestone payments, Anima will have the chance to add three further targets to the partnership under the same terms as the initial collaboration, giving them further scope to increase their collaboration value.

Jonathon Sedgwick, AbbVie’s discovery research vice president and global head, commented: “This collaboration will give AbbVie access to Anima’s leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering and developing drugs to make a difference in patients’ lives. […] Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets with implications across multiple therapy areas.”

Yochi Slonim, Anima’s co-founder and chief executive officer, added: “Anima’s differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. […] The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline.”


Betsy Goodfellow

Related Content

No items found

Latest content